TABLE 2.

Prognostic factors for overall survival of advanced NSCLC patients in univariate Cox regression analyses

Covariates	Statistics	Status
AAPR	0.84 ± 0.36	1.41 (1.11, 1.78) 0.0048
Age
<65	577 (71.41%)	1.0
≥65	231 (28.59%)	1.25 (1.04, 1.51) 0.0182
Gender
Male	556 (68.64%)	1.0
Female	254 (31.36%)	0.80 (0.67, 0.96) 0.0187
Smoking history
Never	385 (47.59%)	1.0
Ever	413 (51.05%)	1.40 (1.17, 1.66) 0.0002
Uncertain	11 (1.36%)	4.06 (2.21, 7.45) <0.0001
ECOG‐PS
0‐1	655 (87.45%)	1.0
≥2	94 (12.55%)	1.52 (1.18, 1.95) 0.0011
Clarification
Adenocarcinoma	593 (73.21%)	1.0
Squamous cell carcinoma	190 (23.46%)	1.38 (1.12, 1.69) 0.0021
Others	27 (3.33%)	1.35 (0.88, 2.07) 0.1749
Clinical stage
IIIB	120 (14.81%)	1.0
IV	690 (85.19%)	1.30 (1.01, 1.67) 0.0418
Bone
No	506 (64.05%)	1.0
Yes	284 (35.95%)	1.14 (0.95, 1.36) 0.1568
Liver
No	673 (85.19%)	1.0
Yes	117 (14.81%)	1.31 (1.03, 1.66) 0.0286
Lung
No	489 (61.90%)	1.0
Yes	301 (38.10%)	1.04 (0.87, 1.25) 0.6563
Brain
No	646 (81.77%)	1.0
Yes	144 (18.23%)	1.11 (0.89, 1.39) 0.3479
Pleural effusion
No	491 (62.15%)	1.0
Yes	299 (37.85%)	0.95 (0.80, 1.14) 0.6042
Number of metastatic organs
≤3	429 (54.30%)	1.0
>3	361 (45.70%)	1.27 (1.07, 1.51) 0.0064
EGFR
Negative	205 (25.31%)	1.0
Positive	137 (16.91%)	0.58 (0.43, 0.79) 0.0005
Unknown	468 (57.78%)	1.15 (0.94, 1.42) 0.1770
ALK
Negative	300 (37.04%)	1.0
Positive	29 (3.58%)	0.73 (0.42, 1.26) 0.2531
Unknown	481 (59.38%)	1.20 (1.00, 1.44) 0.0509
First‐line regiment
Platinum‐based doublet chemotherapy	411 (65.24%)	1.0
Single drug chemotherapy	36 (5.71%)	0.97 (0.64, 1.47) 0.8741
Targeted therapy	125 (19.84%)	0.96 (0.75, 1.24) 0.7588
Platinum‐based doublet chemotherapy plus angiogenesis‐therapy	49 (7.78%)	0.87 (0.58, 1.32) 0.5175
Others	9 (1.43%)	0.00 (0.00, Inf) 0.9888
Number of treatment lines
≤3	489 (76.89%)	1.0
>3	147 (23.11%)	0.59 (0.46, 0.74) <0.0001